Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTPA adjuvant immunotherapy after nephrectomy for renal cell carcinoma
ChiCTR-TRC-13003342Phase 4Recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jul 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pseudomonas aeruginosa injection and interferon alfa in renal cell carcinoma (RCC) (3 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Progression-free survival. Started Jul 2013; status: recruiting.
02
Drugs
pseudomonas aeruginosa injectioninterferon alfa
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR-TRC-13003342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003342.